One of the major regulators of mitosis in somatic cells is cdc25B. cdc25B is tightly regulated at multiple levels. The final activation step involves the regulated binding of 14-3-3 proteins. Previous studies have demonstrated that Ser-323 is a primary 14-3-3 binding site in cdc25B, which influences its activity and cellular localization. 14-3-3 binding to this site appeared to interact with the N-terminal domain of cdc25B to regulate its activity. The presence of consensus 14-3-3 binding sites in the N-terminal domain suggested that the interaction is through direct binding of the 14-3-3 dimer to sites in the N-terminal domain. We have identified Ser-151 and Ser-230 in the N-terminal domain as functional 14-3-3 binding sites utilized by cdc25B in vivo. These low affinity sites cooperate to bind the 14-3-3 dimer bound to the high affinity Ser-323 site, thus forming an intramolecular bridge that constrains cdc25B structure to prevent access of the catalytic site. Loss of 14-3-3 binding to either N-terminal site relaxes cdc25B structure sufficiently to permit access to the catalytic site, and the nuclear export sequence located in the N-terminal domain. Mutation of the Ser-323 site was functionally equivalent to the mutation of all three sites, resulting in the complete loss of 14-3-3 binding, increased access of the catalytic site, and access to nuclear localization sequence.
The partitioning of the replicated genome in mitosis must occur with high fidelity or else the outcome will be an unequal complement of chromosomes in each of the daughter cells. This genomic instability may result in loss of growth suppressors or gain to growth promoters, with a potential for dysregulation of normal growth controls and possibly neoplastic transformation. Thus mechanisms controlling entry into and progression through mitosis must be tightly controlled to ensure the fidelity of this critical process. In all eukaryotes, entry into mitosis is regulated by the activation of cdc2/cyclin B. In higher eukaryotes, the activation of cdc2/cyclin B is controlled not only temporally but spatially. cdc2/cyclin B1 accumulates as an inactive complex in the cytoplasm during G 2 phase. The initial evidence of mitosis is a change in microtubule dynamics and increased microtubule nucleation at the centrosomes. This corresponds to activation of cdc2/cyclin B1 in cytoplasm and at the centrosomes in prophase of mitosis, and occurs before any noticeable mitotic changes occur in the nucleus (1, 2) . Activated cdc2/cyclin B1, and the remaining inactive cdc2/cyclin B1 are translocated into the nucleus, where the latter pool is activated and full mitotic phenotype is observed. The activation of cdc2/ cyclin B in mitosis is regulated by the removal of inhibitory phosphorylations from Thr-14 and Tyr-15 residues in cdc2, catalyzed by the cdc25 family of dual specificity phosphatases. Two isoforms of cdc25, cdc25B, and cdc25C, appear to be responsible for activating cdc2/cyclin B in mitosis (3) (4) (5) . In vivo, cdc25B is active during G 2 phase, before cdc25C is activated at the G 2 /M transition (4, 6, 7) , and cdc25B is more efficient than cdc25C at promoting mitosis (8, 9) . This correlates with the in vitro activity of cdc25B and cdc25C, with the unmodified form of cdc25B able to efficiently activate the cyclin B1/cdc2 kinase complex, whereas only the hyperphosphorylated form of cdc25C efficiently catalyzed this activation (4) . Overexpression of dominant-negative mutants of cdc25B and cdc25C results in a G 2 phase arrest. However, whereas cdc25B dominant-negative overexpression blocked all evidence of mitosis, cells overexpressing the cdc25C dominant-negative mutant often displayed evidence of mitotic events in the cytoplasm, with a complete block in nuclear mitotic events (3) . These data point to cdc25B as the initiator of mitosis, whereas the role of cdc25C is to ensure full activation of cdc2/cyclin B and thereby rapid entry into mitosis. cdc25B itself is tightly regulated at a number of levels. Multiple alternatively spliced forms of cdc25B are expressed, although only the two variants, cdc25B2 and cdc25B3, are expressed as detectable levels of protein (10, 11) . Its protein levels are tightly controlled, accumulating in early G 2 phase and destroyed by proteasome-mediated destruction during early mitosis (12) . It accumulates in the nucleus in early G 2 phase, but at prophase it translocates to cytoplasm, and its appearance in this compartment is tightly associated with the activation of cdc2/cyclin B1 in the cytoplasm and the appearance of cytoplasmic mitotic features such as increased microtubule nucleation at the centrosome and changes in microtubule dynamics (3, 6) . cdc25B is responsible for the activation of not only cdc2/cyclin B1 at prophase, but also appears to control activation of the G 2 phase pool of cdk 1 2/cyclin A during G 2 phase when cdc25B is localized in the nucleus (4, 6, 9) . In normal early G 2 phase and in G 2 phase checkpoint arrested cells, the nuclear localized cdc25B is held in an inactive form as its substrate cdk2/cyclin A is also maintained in its Tyr-15-phosphorylated inactive form.
The mechanism regulating activity and localization of cdc25B involves the binding of 14-3-3 proteins to cdc25B. The 14-3-3 proteins are a highly conserved family of proteins that have important roles in a wide range of cell signaling, cell cycle, and survival pathways (reviewed in Refs. 13 and 14) . The 14-3-3 proteins bind to specific phosphoserine-containing motifs (15) , and their dimeric nature allows them to act as intraand intermolecular, phosphorylation-dependent adaptors (13, 16 ). 14-3-3 binding is a highly conserved mechanism, implicated in the regulation of cdc25 function in organisms from yeast to humans (17, 18 ). cdc25B has a major 14-3-3 binding site at Ser-323, and mutation of this residue to a nonphosphorylatable residue that does not support 14-3-3 binding results in changes in cdc25B localization and increased cdc25B activity (19, 20) . The Ser-323 site is the target for p38MAPK following UV irradiation, which results in stabilizing 14-3-3 binding and blocking entry into mitosis (21) . Thus the factors that control 14-3-3 binding are likely to be important regulators of both normal G 2 /M progression and in the G 2 checkpoint control.
The question of how 14-3-3 binding controls cdc25B functions is not yet fully resolved. The dimeric structure of 14-3-3 suggests it is acting as a molecular adaptor, but to what? Previous work has suggested that 14-3-3 binding to the Ser-323 site alone was not sufficient for down-regulating its activity, and 14-3-3 binding to this site cannot explain the prophase cytoplasmic translocation to cdc25B. In this study we have further investigated the mechanism by which 14-3-3 binding controls cdc25B function. We demonstrate that there are three functional 14-3-3 binding sites, two in the N-terminal regulatory domain and one in the C-terminal catalytic domain. Loss of 14-3-3 binding to either the N-terminal or C-terminal domains influences the localization of cdc25B, although mutation of any of the 14-3-3 binding sites is sufficient to activate cdc25B.
MATERIALS AND METHODS
Cell Culture and Transfections-293H cells (Invitrogen), HeLa, and COS-1 cells were grown in Dulbecco's minimal essential medium (Invitrogen) supplemented with 10% Serum Supreme (BioWhittaker). HeLa and COS-1 cells were transfected by electroporation and 293H cells were transfected using LipofectAMINE 2000 (Invitrogen) following manufacturer's instructions. Transfections were harvested 6 -24 h later for analysis. Leptomycin B, a gift from Dr. M. Yoshida, was added 4 h post-transfection and harvested 8 h for immunofluorescent staining.
Plasmid Constructs and in Binding-pGEX cdc25B3 N-terminal was constructed from full-length pGEX cdc25B3 by digestion with BsrG1 and EcoR1 to remove the C terminus, then treated with DNA polymerase I, large (Klenow) fragment (NEB Biolabs) to fill the 5Ј-sticky ends. The blunt-ended product was recircularized using T4 DNA ligase (NEB Biolabs). The S151A and S230A point mutations were produced using site-directed mutagenesis kit (Stratagene). The double mutant, pGEX cdc25B3 S151A/S230A N terminus, was constructed by subcloning the smaller fragment produced by digesting pGEX cdc25B3 S151A N terminus with NcoI and NotI, into pGEX cdc25B3 S230A N terminus. A further truncation of cdc25B3 to make pGEX cdc25B3 S49 was constructed by subcloning the BstB1-digested fragment of pGEX cdc25B3 N terminus into pGEX-2T vector. The GST-cdc25B3 N terminus proteins were expressed in bacteria, purified using glutathioneagarose and used to examine 14-3-3 binding as described previously (20) . Myc-tagged Cdc25B3 wild type, CR/SK, and S323A mutants were cloned into the pUCSR␣ mammalian expression plasmid as described elsewhere (3, 20) . The triple mutant, pUCSR␣ cdc25B3 S151A/S230A/ S323A, was constructed by subcloning the smaller fragment produced by digesting pGEX cdc25B3 S151A/S230A with BamHI and BsrGI, into pUCSR␣ cdc25B3 S323A. The double mutant, pUCSR␣ cdc25B3 S151A/ S230A, was constructed by subcloning the smaller fragment produced by digesting pUCSR␣ cdc25B3 S151A/S230A/S323A with BamHI and BsrGI, into pUCSR␣ cdc25B3. The single mutant, pUCSR␣ cdc25B3 S151A was constructed by subcloning the smaller fragment produced by digesting pGEX cdc25B3 S151A with BamHI and BsrGI, into pUCSR␣ cdc25B3. The single mutant, pUCSR␣ cdc25B3 S230A was constructed by subcloning the smaller fragment produced by digesting pGEX cdc25B3 S230A with BamHI and BsrGI, into pUCSR␣ cdc25B3. The Myc-tagged 14-3-3 zeta was produced by subcloning 14-3-3 zeta (a gift from Dr. M. Yaffe) into pUCSR␣-Myc. Constructs expressing GST-14-3-3 zeta wild-type and dimerization mutants were gifts from Dr. Y. Tzivion.
Immunoblotting and Immunoprecipitation-Cells were lysed in 14-3-3 lysis buffer (Tris, pH 7.5, 50 mM; NaCl, 150 mM; EGTA, 2 mM; MgSO 4 , 2 mM; Tween 20, 0.1%; dithiothreitol, 5 mM), and a small fraction removed for immunoblotting. The remainder was immunoprecipitated overnight at 4°C with either anti-cdc25B antibody (3) or anti-Myc tag antibody (9B11, Cell Signaling). The antibody complexes were precipitated with 20 l of a 50% slurry of protein A-Sepharose (Amersham Biosciences) washed four times with 14-3-3 lysis buffer and eluted with SDS sample buffer. GST-14-3-3 zeta expressed in HeLa cells was affinity-purified from similarly prepared lysates using glutathione-agarose and eluted with SDS sample buffer. Samples were resolved on 10% SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with either anti-Myc tag, anti-cdc25B, anti-GST, anticdc2, anti-pan 14-3-3 or anti-cyclin B1 antibodies (3), detected using ECL (PerkinElmer Life Sciences).
Immunofluorescent Staining-293H cells grown on glass coverslips overnight were transfected and washed once with PBS at 8 -24 h post-transfection. Asynchronously growing or etoposide-treated, G 2 phase arrested Hela cells were transfected and plated onto glass coverslips. Cells were washed once with PBS at 8 h post-transfection. Cells were then fixed with Ϫ20°C methanol and stored overnight at Ϫ20°C until required. For immunostaining, cells were washed with PBS, then rehydrated with PBS containing 0.1% Tween 20, 0.05% sodium azide, and 3% bovine serum albumin for 30 min at room temperature. Cells were stained with primary antibody, mouse anti-␣-tubulin (1:1000, Sigma Aldrich), and rabbit anti-Cdc25B (1:200, Santa Cruz Biotechnology), for 1 h at room temperature in 3% bovine serum albumin. The coverslips were washed four times in PBS containing 0.1% skim milk powder for 5 min, and cells were stained with fluorophore-conjugated secondary antibody/anti-mouse Cy3 (1:200, Zymed Laboratories Inc.) and anti-rabbit FITC (1:200, Silenus), and the DNA was stained with either 1 g/ml propidium iodide or 10 g/ml DAPI for 1 h at room temperature. The coverslips were washed again as above and mounted onto microscope slides using Vecta Shield to preserve fluorescence.
Gel Filtration Analysis-293H and HeLa cells were transfected with either pUCSR␣-Myc Cdc25B3 wild type, S323A, or triple mutant, then harvested 8 h post-transfection, and cell pellets were stored at Ϫ80°C until required. Cells were lysed in 300 l of 14-3-3 lysis buffer and precleared by centrifuging the lysate twice at 12,000 rpm for 15 min in a microcentrifuge at 4°C before loading onto the Superose 12 column (Amersham Biosciences). The column was equilibrated in 14-3-3 buffer (without Tween 20) and eluted at a flow rate of 300 l/min. 300-l fractions were collected after an initial volume of 7 ml. Protein fractions were precipitated overnight in 4 volumes of acetone at Ϫ80°C and proteins pelleted by centrifugation at 12,000 rpm for 30 min in a microcentrifuge. Pellets were dissolved in SDS sample buffer and proteins resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted for cdc25B and 14-3-3.
RESULTS

Identification of cdc25B N-terminal 14-3-3 Binding Sites-
Previously, we have found that mutation of the Ser-323 site on cdc25B resulted in a dramatic reduction in 14-3-3 binding, although not a complete loss (20) . This suggested that there were other sites capable of supporting 14-3-3 binding. Our data had also suggested that 14-3-3 binding to Ser-323 alone was insufficient to explain the regulation of cdc25B activity, but that this also involved the N-terminal regulatory domain. Together these findings suggested that there were important regulatory 14-3-3 binding sites in the N-terminal domain of cdc25B. This region contains three sequences that conform to the consensus, phosphorylation-dependent 14-3-3 binding site, RX 1-2 SPXP (Fig. 1A) . To identify which of these sites were capable of supporting 14-3-3 binding in vitro, bacterially expressed GST-cdc25B3 N-terminal protein fragments (residues 1-311 of cdc25B3, Ref.
3) were produced with point mutations of the Ser residues Ser-151 and Ser-230 changed to Ala, either individually or in tandem, and a truncation of the N terminus that included only the Ser-49 site deleting the Ser-151 and Ser-230 sites (Fig. 1B) . The GST fusion proteins were incubated in HeLa cell extracts, or extracts supplemented with MgSO 4 or MgSO 4 and ATP to support phosphorylation. 14-3-3 binding was detected by immunoblotting. The wild-type Nterminal sequence bound 14-3-3 in the presence of Mg 2ϩ and ATP, and the individual S151A and S230A mutants retained Mg 2ϩ /ATP-dependent 14-3-3 binding, albeit a reduced level, whereas the double S151/230A mutant bound only background levels of 14-3-3, which did not increase with the addition of Mg 2ϩ /ATP ( Fig. 2A) . The Ser-49 only containing truncation also bound only background levels of 14-3-3, which was insensitive to Mg 2ϩ /ATP addition, demonstrating that this site was incapable of supporting 14-3-3 binding. Thus only the Ser-151 and Ser-230 sites are viable 14-3-3 binding sites.
To examine the utilization of the in vitro identified 14-3-3 binding sites in vivo, HeLa cells were transfected with Myctagged cdc25B3 wild type and versions containing individual 14-3-3 binding sites mutations including the originally identified Ser-323 site, tandem mutation of the Ser-151 and Ser-230 sites, and mutation of all three sites (triple), together with Myc-tagged 14-3-3 zeta. Cdc25B3 was used as it is the major spliced form of cdc25B expressed and all the 14-3-3 binding sites are completely conserved in all cdc25B splice variants (11) . Lysates prepared from the transfected cells were immunoprecipitated with an anti-cdc25B antibody, and the immunoprecipitates were analyzed for cdc25B and Myc-14-3-3 binding. The S323A mutant displayed severely reduced 14-3-3 binding compared with wild-type protein, whereas individual Ser-151 and Ser-230 mutants displayed wild-type levels. The Ser-151 Ser-230 double mutant displayed a 50% decrease in binding, and the triple mutant did not bind 14-3-3 (Fig. 2B ). This confirms Ser-151 and Ser-230 are in vivo 14-3-3 binding sites, although they appeared to be mutually redundant, with a significant reduction in 14-3-3 binding only observed with mutation of both these sites. The complete loss of 14-3-3 binding in the triple mutant confirmed Ser-151, Ser-230, and Ser-323 as the only 14-3-3 binding sites in cdc25B.
Mutation of N-terminal 14-3-3 Binding Sites Activate cdc25B-We have previously shown that S323A mutation is sufficient to activate cdc25B (20) . However, deletion of the N-terminal domain was also activating, suggesting that 14-3-3 binding to the Ser-323 site was interacting with the N-terminal domain to regulate cdc25B activity. The dimeric structure of 14-3-3 suggested that the 14-3-3 dimer binding to Ser-323 could interact with 14-3-3 binding sites in the N-terminal domain. This model would predict that mutation of the N-terminal 14-3-3 binding sites should also be activating mutations. To test this, substrate trapping mutants of cdc25B (cdc25B CR/SK mutations, Refs. 20) incorporating 14-3-3 binding site mutations, S323A, the tandem S151A/S230A N-terminal site mutations, or the triple mutant, were expressed in 293H cells. The cdc25B immunoprecipitates were immunoblotted for cdc25B and bound cdc2/cyclin B1 substrate. All the 14-3-3 binding site mutants displayed high levels of cdc2/cyclin B1 binding compared with equivalent levels of cdc25B2 and cdc25B3 with wild-type 14-3-3 binding sites, indicating that tandem mutation of the N-terminal 14-3-3 binding sites was sufficient to activate cdc25B (Fig. 3A) . The activity of the cdc25B 14-3-3 binding site mutants was also assessed by their relative ability to activate endogenous cdc2/cyclin B1 when transiently overexpressed in etoposide-treated, G 2 phase-arrested HeLa cells (20) . This assay demonstrated that the individual site mutants were activating mutations with similar activity to the S323A mutant, and increased activity compared with the wild-type protein, supporting the assignment of these mutations as activating mutations (Fig. 3B) . Interestingly, the tandem S151A/ S230A mutant and triple mutant had increased activity compared with individual site mutants, suggesting that mutation of individual sites was not sufficient to completely abrogate the regulatory effect of 14-3-3 binding. The ability of the overexpressed cdc25B to force etoposide-arrested G 2 phase cells into mitosis was also assessed by counting the number of cdc25B overexpressing cells displaying a mitotic phenotype at 8 h after transfection. All the 14-3-3 binding site mutants had similar   FIG. 1. Consensus 14-3-3 binding sites in cdc25B. A, the consensus 14-3-3 binding site (in italics, the phosphorylated Ser residue has an asterisk) aligned with the three potential sites in the cdc25B N-terminal domain. B, schematic representation of cdc25B3 sequence showing the relative positions of the potential 14-3-3 binding sites, the NES, NLS, and the alternatively spliced exon. The relative positions of the truncations produced by BstB1 and BsrG1 digestion of the full-length cdc25B3 cDNA are shown.
FIG. 2. Identification of the 14-3-3 binding sites in cdc25B.
A, bacterially expressed GST fusion products of cdc25B3 N-terminal domain (residues 1-311), either wild type (wt), individual S151A and S230A mutants, the tandem S151A/S230A mutant, and the N-terminal truncation containing only the Ser-49 site were used to examine the in vitro binding of 14-3-3. The glutathione-agarose-bound GST fusion products were incubated in HeLa cell lysates supplemented as indicated, washed then analyzed by immunoblotting with an anti-GST antibody to show the levels of the GST-N-terminal fusion proteins, and with a pan isoform 14-3-3 antibody to terminal bound 14-3-3. B, HeLa cells were transfected with either empty vector (vec), cdc25B3 wild type (wt), or the indicated 14-3-3 binding site mutant, without or with myc-14-3-3 zeta, then harvested after 8 h. Lysates of these cells were immunoprecipitated with anti-cdc25B, and lysates (as input control) and immunopreciptates were immunoblotted for Myc-tagged cdc25B and 14-3-3 zeta.
ability to force cells into mitosis, although in this measure the individual Ser-151 and Ser-230 had slightly lower activity than the other mutants (Fig. 3C ).
14-3-3 Acts as an Intramolecular Bridge to Regulate cdc25B Activity-The finding that disruption of either N-terminal or C-terminal 14-3-3 binding sites on cdc25B was sufficient to activate its phosphatase activity suggested that loss of binding to either the N-terminal or C-terminal domains of the protein was sufficient to permit increased access of the substrate to the catalytic site of the enzyme. This was demonstrated directly with the increased cdc2/cyclin B1 binding to the substratetrapping mutants (Fig. 3A) . The apparent equivalence of the 14-3-3 binding sites in terms of their ability to regulate cdc25B activity was difficult to reconcile with the very different consequences of the mutations on 14-3-3 binding. One plausible explanation was that the dimeric 14-3-3 molecule was acting as an intramolecular bridge, and thus loss of binding from either the N-or C-terminal sites resulted in the disruption of the bridge and increased access to the catalytic site of cdc25B. Another possible model was that dimeric 14-3-3 was acting as an adaptor linking two molecules of cdc25B, with two 14-3-3 dimers linking the cdc25B in a head-to-tail fashion to bring the catalytic domain of one cdc25B in close contact with the regulatory domain of the second cdc25B. To examine whether 14-3-3 was acting as an intra-or intermolecular bridge, cells overexpressing cdc25B3 wild type, S232A, or the triple mutant were analyzed by gel filtration chromatography on a Superose 12 column. Wild-type cdc25B3 eluted as a broad peak with a shoulder eluting with an apparent molecular size of 120 kDa whereas the S323A mutant eluted with an apparent molecular size of 80 kDa (Fig. 4) . cdc25B3 has an apparent molecular mass of 75 kDa determined by SDS-PAGE despite its calculated molecular mass of only 62 kDa (3) . In a number of separate experiments, the proportion of cdc25B3 wild type eluting in the 120 and 80 kDa size ranges was variable, but in all experiments wild-type cdc25B3 eluted across this molecular size range. By contrast, the S323A mutant always eluted as single peak of 80 kDa. The triple mutant behaved identically to the S323A mutant (data not shown) indicating that the loss of 14-3-3 binding was likely to be responsible for the reduced molecular size of these mutants.
When similar fractions were immunoblotted for 14-3-3 using as a pan isoform antibody, the major peak of 14-3-3 eluted with a molecular size of 50 kDa, the expected size of the 14-3-3 dimer, although low levels of 14-3-3 were detected across all fractions. The 120-kDa shoulder of cdc25B3 wild type corresponds to the approximate size of monomeric cdc25B and a dimer of 14-3-3, making it unlikely that 14-3-3 was bridging two molecules of cdc25B. Moreover, it was unlikely that cdc25B was complexed with an unidentified protein via a 14-3-3 dimer, although the possibility of a small proportion of cdc25B doing so, or this protein having a low molecular weight and therefore difficult to detect by this analysis, cannot be discounted.
FIG. 3. Mutation of 14-3-3 binding sites activate cdc25B.
A, 293H cells were transfected with either empty vector (vec) or substratetrapping mutants of cdc25B2 (B2), cdc25B3 (B3), or substrate-trapping version of cdc25B3 containing the indicated 14-3-3 binding site mutations. Anti-cdc25B immunoprecipitates were immunoblotted for cdc25B and the bound cyclin B1 and cdc2. B, etoposide-treated, G 2 phasearrested HeLa cells were transfected with either empty vector, catalytically inactive (CR/SK), wild type (WT), or indicated 14-3-3 binding site mutant of cdc25B3. Cells were harvested after 8 h and the activity of the endogenous cdc2/cyclin B1 assayed as a measure of cdc25B activity. Data are expressed as percentage increase over the inactive cdc25B3 CR/SK mutant and represent the mean and S.D. from at least three independent experiments. C, etoposide-treated HeLa cells, transfected, and harvested as in B, were fixed and immunostained for cdc25B, ␣-tubulin, and DNA. The percentage of cdc25B-overexpressing cells displaying a mitotic phenotype was counted. For each condition at least 100 cdc25B3-overexpressing cells were counted. The data represent the mean and S.D. from three independent experiments.
FIG. 4. Cdc25B is only associated with dimeric 14-3-3.
A, HeLa cells transfected with either cdc25B3 wild type (25B3 wt) or the S323A mutant were fractionated on a Superose 12 gel filtration column. Fractions collected were immunoblotted for cdc25B and 14-3-3 with a pan 14-3-3 isoform antibody. The apparent molecular size of the peak fractions and the elution position of bovine serum albumin and ovalbumin (66 and 43 kDa markers) are shown. These data are typical of at least three independent experiments. B, densitometry of the levels of cdc25B detected in the immunoblots shown in A.
The model of 14-3-3 acting as an intramolecular bridge would predict that 14-3-3 mutants that are defective in dimerizing should increase access of the cdk/cyclin substrates to the active site of cdc25B, thereby increasing its phosphatase activity. This was directly tested using the GST-14-3-3 zeta dimerization mutant used previously to demonstrate that the 14-3-3 dimer was essential to regulate Raf-1 activity (22) . The zeta isoform of 14-3-3 has been demonstrated to be a preferred binding partner of cdc25B (23) . When wild-type GST-14-3-3 zeta was co-expressed with wild-type cdc25B3 substrate trapping mutant, the level of bound cdc2/cyclin B1 was below the level associated with either cdc25B transfected alone or transfected with the dimerization mutant of 14-3-3 zeta (Fig. 5A) . Although the dimerization mutant was expressed at a similar level to the wild type GST-14-3-3 zeta, it bound cdc25B with lower avidity than the wild-type protein, demonstrated by the lower level of cdc25B3 associated with the GST-14-3-3 proteins in glutathione bead pull-down analysis, despite similar levels of cdc25B3 being expressed in these cells (Fig. 5, B and C) . These data suggest that the GST-14-3-3 dimerization mutant effectively reduced 14-3-3 binding to cdc25B, thereby increasing access to the catalytic site.
14-3-3 Binding Regulates cdc25B Localization-The localization of endogenous cdc25B changes during the cell cycle, accumulating in the nucleus during late S and G 2 phase, then relocating to the cytoplasm at prophase just prior to nuclear envelope breakdown (3, 6) . The question of what regulates this change in localization is still poorly understood, although loss of 14-3-3 binding to the Ser-323 site resulted in a complete loss of cytoplasmic localization (19) . cdc25B contains a functional nuclear export sequence (NES) located in the N terminus of the protein between residues 28 and 40 (19) . The Ser-323 14-3-3 binding site is proximal to the nuclear localization sequence (NLS). Although the NES is close to the N terminus of the protein, the N-terminal 14-3-3 binding sites may influence access to this sequence (Fig. 1B) . The localization of cdc25B3 14-3-3 binding site mutants was examined in asynchronously growing HeLa cells 8 h after transient transfection, when the majority of transfected cells were still in G 1 or S phase. The localization of the wild-type protein was predominantly nuclear or nuclear and cytoplasmic, whereas the S323A and triple mutants where exclusively nuclear (Fig. 6, A and B) . Interestingly, mutation of either Ser-151 or Ser-230 individually or in tandem caused a striking increase in strictly cytoplasmic localization of cdc25B, the tandem mutations giving a slightly higher proportion of cells with cytoplasmic localization than the individual mutants. The loss of the Ser-323 14-3-3 binding site appeared to have a dominant effect over the cytoplasmic FIG. 5 . Dimeric 14-3-3 binding to cdc25B blocks substrate access to the catalytic site. COS-1 cells were transfected with either empty vector (vec), or the substrate-trapping version of cdc25B3 wild type, and co-transfected with either empty vector, GST-14-3-3 zeta wild type (wt) or dimerization mutant (dm). A, anti-cdc25B immunoprecipitates were immunoblotted for cdc25B and bound substrate cdc2 and cyclin B1. B, the level of GST-14-3-3 zeta and associated cdc25B was determined by glutathione-agarose precipitation and immunoblotting for the GST-14-3-3 and cdc25B. C, lysates from the transfections were immunoblotted for the overexpressed cdc25B. These data were typical of three independent experiments.
FIG. 6. Mutation of 14-3-3 binding sites changes localization of cdc25B.
A, immunofluorescent micrographs of HeLa cells overexpressing cdc25B3 S151A/S230A (top and middle) and cdc25B3 triple mutant (bottom). Cells were stained for cdc25B and propidium iodide (PI) for DNA and demonstrate the three localizations of cdc25B, cytoplasmic (top), nuclear and cytoplasmic (middle), nuclear (bottom). B, HeLa cells transfected with the indicated cdc25B3 were fixed after 8 h, immunostained as in A and the localization of cdc25B quantitated. The data represent at least 100 cdc25B overexpressing cells in each transfection and are the mean and S.D. of three independent experiments. Similar data were obtained with transfection into 293H cells (data not shown). C, 293H cells transfected with cdc25B3 S151A/S230A were treated either without or with leptomycin B for 4 h. Cells were then fixed and stained as in A. Leptomycin B treatment caused the complete relocalization of cdc25B into the nucleus. localization resulting from mutation of the N-terminal 14-3-3 binding sites, with the triple mutant localizing almost exclusively to the nucleus similar to the S323A mutant.
The cytoplasmic localization caused by the N-terminal site mutations may have been a consequence of either a loss of NLS function or an increased nuclear export due to increased influence of the N-terminal NES. To differentiate between these possibilities, the effect of the nuclear export inhibitor leptomycin B on cdc25B3 S151/230A tandem mutant localization was examined. Whereas normally Ͼ70% of cells expressing this mutant displayed only cytoplasmic or cytoplasmic and nuclear accumulation of the protein, after 4 h of leptomycin B treatment 100% of cells displayed only nuclear staining for this mutant (Fig. 6C) . Thus the cytoplasmic localization was a consequence of increased influence of the N-terminal NES over the C-terminal NLS.
These data provide evidence that the binding of 14-3-3 to different sites on cdc25B strongly influences the cellular localization of the protein. However, the localization of cdc25B may not be solely controlled by site-specific 14-3-3 binding. When the 14-3-3 binding site mutants were expressed in etoposidetreated, G 2 phase arrested HeLa cells, a significant change in cellular localization was observed when compared with the transfections into asynchronously growing cells, which were predominantly G 1 and S phase. Wild type and all mutants displayed a higher level of cytoplasmic localization, both cytoplasmic only and cytoplasmic and nuclear, when expressed in etoposide-treated cells (Fig. 7A ) compared with the asynchronous cultures (Fig. 6B) . This was particularly evident with the S323A and triple mutants, which were almost exclusively nuclear in the asynchronous cultures but displayed significant levels of cytoplasmic expression when expressed in the etoposide-treated cells. Interestingly, this contrasted with endogenous cdc25B, which displayed exclusively nuclear staining in the same cultures (Fig. 7B) . The increased cytoplasmic staining may be a consequence of the overexpressed cdc25B pushing the etoposide-treated, G 2 arrested cells into mitosis, and the high proportion of mitotic cells detected in all the mutant cdc25B-overexpressing cultures (Fig. 7A) . The cdc25B wild-type-overexpressing cells also displayed an increased cytoplasmic staining for cdc25B, even though few mitotic cells were detected. Wild-type cdc25B is a weaker activator of endogenous cdc2/ cyclin B than the mutants (Fig. 3, A and B) , but it will eventually overcome arrest and cause cells to undergo mitosis (20) . Thus wild-type cdc25B3-overexpressing cells are also transiting into mitosis, albeit slower than the mutants. The increased cytoplasmic localization suggests that there are other factors acting during progression through G 2 into mitosis that influence cdc25B cytoplasmic localization, probably cooperating with 14-3-3 binding to regulate its cytoplasmic localization at the G 2 /M transition.
DISCUSSION
Here we have demonstrated that cdc25B activity is regulated by the binding to 14-3-3. Cdc25B contains three functional 14-3-3 binding sites Ser-151, Ser-230, and Ser-323, and mutation of all these sites to the nonphosphorylatable Ala residue is required to completely abrogate 14-3-3 binding to cdc25B. The Ser-323 site is highly conserved between human cdc25B and cdc25C, and is also conserved in all mammalian cdc25B sequences. The Ser-230 site is also well conserved among mammalian cdc25B sequences whereas the Ser-151 site is poorly conserved, indicating that all mammalian cdc25Bs possess functional N-and C-terminal domain 14-3-3 binding sites.
The model for 14-3-3 binding and regulation of cdc25B activity must account for the dimeric nature of 14-3-3, the presence of functional 14-3-3 binding sites in the N-and C-terminal domains of cdc25B, the finding that all 14-3-3 site mutations are activating mutations, the ability of the dimerization mutant to increase accessibility to the active site of cdc25B, and the molecular size of the cdc25B complex suggesting the presence of only a cdc25B monomer and a 14-3-3 dimer. We propose that 14-3-3 is acting as an intramolecular bridge, constraining the N-terminal in such a way that it blocks access of the substrate cdk/cyclins to the catalytic site in the C-terminal domain of cdc25B when bound to both N-and C-terminal 14-3-3 binding sites (Fig. 8A) . Loss of the bidentate binding results in a relaxation of cdc25B structure and increased access to the catalytic site (Fig. 8, B and C) . This model is similar to that proposed for the regulation of Raf-1 activity (22) 14-3-3 binding. Cdc25B is held in an inactive state by dimeric 14-3-3 forming an intramolecular bridge from the major Ser-323 site to either of the N-terminal sites which are in equilibrium (A). Mutation of the Ser-323 site, which is equivalent to the triple mutant in terms of 14-3-3 binding results in increased access to the catalytic site (HCXXXXXR) as well as the NES and NLS. The NLS must be dominant resulting in nuclear localization (B). Mutation of the N-terminal sites has little effect on 14-3-3 binding to Ser-323 but results in opening up of the structure permitting increased access to the catalytic site and the NES. 14-3-3 binding to the Ser-323 site must hinder access to the NLS resulting in dominance of the NES (C).
14-3-3 binds to inactive Raf-1 at Ser-259 and Ser-621 to maintain it in an inactive state, and disruption of either Ser-259 or Ser-621 binding is sufficient to permit activation of Raf-1 (24) . This model of dimeric 14-3-3 binding to cdc25B N-and Cterminal domains supports the "molecular anvil" model for 14-3-3 proposed by Yaffe (25) . cdc25B clearly has a high affinity 14-3-3 binding site, the Ser-323 site. Loss of the N-terminal 14-3-3 binding sites have only a small effect on 14-3-3 binding whereas loss of the Ser-323 site results in a severe reduction in binding. The Ser-151 and Ser-230 sites appear to cooperate in binding 14-3-3 anchored to the Ser-323 site, and even though mutation of a single N-terminal site had little effect on 14-3-3 binding to cdc25B, the single mutants had similar activity as the S151A/S230A tandem mutant, evidence that loss of a single N-terminal site was sufficient to destabilize the intramolecular bridge and open the structure of cdc25B to increase accessibility to the catalytic site. In this model, 14-3-3 anchored to the Ser-323 high affinity sites is in a binding equilibrium between the Ser-151 and Ser-230 sites (Fig. 8A) . Thus loss of a single N-terminal site pushes the equilibrium toward the more open conformation, although loss of both sites further increases the likelihood of the open conformation.
14-3-3 binding also influences cdc25B localization. It has been previously shown that mutation of Ser-323 causes cdc25B to localize strictly to the nucleus (19) . Here we have shown that mutation of either N-terminal 14-3-3 binding site increases the cytoplasmic localization of cdc25B. The proximity of the NLS to the Ser-323 site and NES to the N-terminal sites suggests that the binding of 14-3-3 to these sites influences the accessibility of transport chaperones to these sequences (Fig. 1B) . Loss of 14-3-3 binding to Ser-323 site would appear to increase access to the NLS, increasing the localization of this mutant protein to the nucleus as observed (Fig. 8B) . Loss of 14-3-3 binding to the N-terminal sites, which has little effect on 14-3-3 binding to the Ser-323 site, indicated by the high level of 14-3-3 binding to even the S151A/S230A tandem mutant, must increase access to NES in the N-terminal domain and perhaps the 14-3-3 binding to the Ser-323 site inhibits access to the NLS, resulting in an increased export from the nucleus (Fig. 8C) . Complete loss of 14-3-3, or mutation of only the Ser-323 site favors nuclear import and retention. The wild-type protein shows a predominantly nuclear only or nuclear and cytoplasmic localization, suggesting that the conformation of the cdc25B with bidentate 14-3-3 binding favors nuclear import and retention, although some shuttling is likely to occur. However, the observation that as cells progress through G 2 phase into mitosis, even the strictly nuclear S323A and triple mutants display increased cytoplasmic localization is evidence that other factors also regulate cdc25B localization. It is likely that the extensive mitotic phosphorylation of the N-terminal domain is involved, which may influence 14-3-3 binding to the N-terminal sites and perhaps localization by other mechanisms. A recent report has demonstrated that Ser-146 in the cdc25B1 splice variant (equivalent to Ser-160 in the cdc25B3 sequence) is phosphorylated in mitosis, and mutation of this site to Gly resulted in the increase cytoplasmic localization of the mutant protein (26) . Phosphorylation at the Ser-160 site might influences 14-3-3 binding to the Ser-151 14-3-3 binding site, although it would seem more probable that phosphorylation at this site would inhibit 14-3-3 binding and thereby cause the cytoplasmic localization. These authors have demonstrated that other phosphorylations of the N-terminal domain occur, and these may also influence 14-3-3 binding to the N-terminal of cdc25B and its cytoplasmic export.
The regulation and utilization of the N-terminal 14-3-3 binding sites may also vary for the individual cdc25B splice variants. The Ser-151 site is immediately adjacent to the exon spliced out of the cdc25B2 variant (Fig. 1B) , which may effect the utilization of this in the B2 variant. The exon contains the Ser-160, and Ser-186 and Ser-187 sites phosphorylated by cdc2/ cyclin B and casein kinase 2, respectively (26, 27) , suggesting that the regulation of the Ser-151 site in cdc25B2 is likely to be different from the other cdc25B variants.
In this report we have demonstrated that the activity and localization of cdc25B is regulated by the binding of a dimer of 14-3-3 to sites in the N-and C-terminal domains of the protein, acting as an intramolecular bridge to constrain the protein such that access to the catalytic site is restricted as is access to the NES. The loss of 14-3-3 binding to any of the sites on cdc25B is sufficient to activate the protein, but loss of binding to the N-terminal or C-terminal domains results in increased nuclear export and nuclear localization, respectively. The kinases that phosphorylate these 14-3-3 binding sites will be important regulators of cdc25B activity, but perhaps more importantly, the factors that disrupt binding to the N-and Cterminal sites will be critical activators of cdc25B. It is likely that different factors will regulate the disruption of N-and C-terminal 14-3-3 binding as the outcomes in terms of localization of the protein are very different. It would be expected that loss of binding to the C-terminal domain occurs during G 2 phase resulting in the activation of cdc25B while retaining it in the nucleus to activate the G 2 phase pool of cdk2/cyclin A, whereas cytoplasmic localization of cdc25B in prophase is likely to involve the disruption of only the N-terminal binding sites. The loss of binding to these sites may not necessarily involve dephosphorylation of the binding site serine residues. In Raf-1 activation, a major role of Ras is to disrupt binding to 14-3-3 to the phosphorylated Ser-259 site (22) . Although it is unlikely that a similar protein interaction will be involved, the mechanism for disruption of this influential binding event is at present unknown. Once the 14-3-3 binding is disrupted then phosphatases may dephosphorylate the 14-3-3 binding sites. The demonstration that p38MAPK is able to phosphorylate the Ser-323 site in response to ultraviolet radiation insult is evidence that this site must be dephosphorylated at some stage in G 2 /M progression. Although the timing of these events and the identity of the factors involved are still to be defined, it is clear from the evidence presented here that regulation of 14-3-3 binding to the N-and C-terminal sites in cdc25B is a major mechanism regulating cdc25B function.
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